Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Parallel-Controlled Phase IIb Clinical Trial of PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection Integrated With 18F-FDG for the Assessment of Myocardial Viability in Patients With Ischemic Cardiomyopathy

NCT07443696 is registered in ClinicalTrials.gov with Sinotau Pharmaceutical Group as lead sponsor.

NCT NCT07443696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07443696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Parallel-Controlled Phase IIb Clinical Trial of PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection Integrated With 18F-FDG for the Assessment of Myocardial Viability in Patients With Ischemic Cardiomyopathy
Lead sponsor
Sinotau Pharmaceutical Group
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2025
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, ischemic cardiomyopathy